Handok

Handok P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Handok (002390.KS) as of Oct 21, 2026 is -13.00. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -6.95 — a change of 87.15% (lower).

P/FCF

-13.00

YoY

87.15%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Handok is 2025 -13.00 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Handok was 2024 -6.95 . It decreases by 87.15% lower compared to the previous year.

The Handok P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
11.26 KRW
Jan 1, 2019
-11.65 KRW
Jan 1, 2020
39.49 KRW
Jan 1, 2021
-26.63 KRW
Jan 1, 2022
-27.11 KRW
Jan 1, 2023
15.73 KRW
Jan 1, 2024
-6.95 KRW
Jan 1, 2025
-13.00 KRW
The Handok P/FCF history
YEARP/FCFYoY
-13.00+87.15%
-6.95-144.17%
15.73-158.01%
-27.11+1.81%
-26.63-167.43%
39.49-439.04%
-11.65-203.44%
11.26-263.36%
-6.89+79.72%
-3.84-104.88%
78.57+1,152.01%
6.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Handok stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Handok is -13.00 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Handok changed from -6.95 to -13.00, representing a 87.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Handok since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Handok with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Handok

All Key Metrics — Handok